Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis: Twelve-month outcomes

Ashvini Reddy, Mariana Cabrera, Steven Yeh, Janet L. Davis, Thomas A. Albini

Research output: Contribution to journalArticle

Abstract

Purpose: To determine whether serial ranibizumab injections are effective in the treatment of cystoid macular edema in patients with chronic controlled noninfectious uveitis.

Methods: Five eyes of 5 patients were included in a prospective noncomparative therapeutic trial. They received intravitreal injections of ranibizumab at Day 0 and were followed monthly for 1 year. Injections were repeated monthly if persistent or new cystic edema manifested on optical coherence tomography. The primary outcome measure was the mean change in best-corrected visual acuity from baseline at 12 months. Secondary outcome measures included mean percentage change in central subfield retinal thickness (CST) and incidence of adverse events through Month 24.

Results: Thirty-two injections were performed over the study period. At 1 year, the mean increase in acuity was 12.2 Early Treatment for Diabetic Retinopathy Study letters (P = 0.015). There was a statistically significant increase in visual acuity over time (P = 0.002). The CST decreased by 31.4%, 46.0%, 37.6%, and 45.4% relative to baseline at 3, 6, 9, and 12 months, respectively (P = 0.003). One patient experienced recurrence of uveitis with subsequent cataract and glaucoma progression.

Conclusion: Optical coherence tomography-guided monthly intravitreal ranibizumab injections delivered over the course of 1 year resulted in improved vision and reduced central retinal thickness.

Original languageEnglish (US)
Pages (from-to)2431-2438
Number of pages8
JournalRetina
Volume34
Issue number12
StatePublished - Dec 11 2014
Externally publishedYes

Fingerprint

Macular Edema
Uveitis
Optical Coherence Tomography
Intravitreal Injections
Injections
Visual Acuity
Outcome Assessment (Health Care)
Low Vision
Diabetic Retinopathy
Glaucoma
Cataract
Edema
Therapeutics
Recurrence
Incidence
Ranibizumab

Keywords

  • Anti-vascular endothelial growth factor
  • Antiangiogenics
  • Cystoid macular edema
  • Ranibizumab
  • Uveitic macular edema
  • Uveitis

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Reddy, A., Cabrera, M., Yeh, S., Davis, J. L., & Albini, T. A. (2014). Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis: Twelve-month outcomes. Retina, 34(12), 2431-2438.

Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis : Twelve-month outcomes. / Reddy, Ashvini; Cabrera, Mariana; Yeh, Steven; Davis, Janet L.; Albini, Thomas A.

In: Retina, Vol. 34, No. 12, 11.12.2014, p. 2431-2438.

Research output: Contribution to journalArticle

Reddy, A, Cabrera, M, Yeh, S, Davis, JL & Albini, TA 2014, 'Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis: Twelve-month outcomes', Retina, vol. 34, no. 12, pp. 2431-2438.
Reddy, Ashvini ; Cabrera, Mariana ; Yeh, Steven ; Davis, Janet L. ; Albini, Thomas A. / Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis : Twelve-month outcomes. In: Retina. 2014 ; Vol. 34, No. 12. pp. 2431-2438.
@article{6135c6efbcc94207b6342617893fe4d9,
title = "Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis: Twelve-month outcomes",
abstract = "Purpose: To determine whether serial ranibizumab injections are effective in the treatment of cystoid macular edema in patients with chronic controlled noninfectious uveitis.Methods: Five eyes of 5 patients were included in a prospective noncomparative therapeutic trial. They received intravitreal injections of ranibizumab at Day 0 and were followed monthly for 1 year. Injections were repeated monthly if persistent or new cystic edema manifested on optical coherence tomography. The primary outcome measure was the mean change in best-corrected visual acuity from baseline at 12 months. Secondary outcome measures included mean percentage change in central subfield retinal thickness (CST) and incidence of adverse events through Month 24.Results: Thirty-two injections were performed over the study period. At 1 year, the mean increase in acuity was 12.2 Early Treatment for Diabetic Retinopathy Study letters (P = 0.015). There was a statistically significant increase in visual acuity over time (P = 0.002). The CST decreased by 31.4{\%}, 46.0{\%}, 37.6{\%}, and 45.4{\%} relative to baseline at 3, 6, 9, and 12 months, respectively (P = 0.003). One patient experienced recurrence of uveitis with subsequent cataract and glaucoma progression.Conclusion: Optical coherence tomography-guided monthly intravitreal ranibizumab injections delivered over the course of 1 year resulted in improved vision and reduced central retinal thickness.",
keywords = "Anti-vascular endothelial growth factor, Antiangiogenics, Cystoid macular edema, Ranibizumab, Uveitic macular edema, Uveitis",
author = "Ashvini Reddy and Mariana Cabrera and Steven Yeh and Davis, {Janet L.} and Albini, {Thomas A.}",
year = "2014",
month = "12",
day = "11",
language = "English (US)",
volume = "34",
pages = "2431--2438",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams and Wilkins",
number = "12",

}

TY - JOUR

T1 - Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis

T2 - Twelve-month outcomes

AU - Reddy, Ashvini

AU - Cabrera, Mariana

AU - Yeh, Steven

AU - Davis, Janet L.

AU - Albini, Thomas A.

PY - 2014/12/11

Y1 - 2014/12/11

N2 - Purpose: To determine whether serial ranibizumab injections are effective in the treatment of cystoid macular edema in patients with chronic controlled noninfectious uveitis.Methods: Five eyes of 5 patients were included in a prospective noncomparative therapeutic trial. They received intravitreal injections of ranibizumab at Day 0 and were followed monthly for 1 year. Injections were repeated monthly if persistent or new cystic edema manifested on optical coherence tomography. The primary outcome measure was the mean change in best-corrected visual acuity from baseline at 12 months. Secondary outcome measures included mean percentage change in central subfield retinal thickness (CST) and incidence of adverse events through Month 24.Results: Thirty-two injections were performed over the study period. At 1 year, the mean increase in acuity was 12.2 Early Treatment for Diabetic Retinopathy Study letters (P = 0.015). There was a statistically significant increase in visual acuity over time (P = 0.002). The CST decreased by 31.4%, 46.0%, 37.6%, and 45.4% relative to baseline at 3, 6, 9, and 12 months, respectively (P = 0.003). One patient experienced recurrence of uveitis with subsequent cataract and glaucoma progression.Conclusion: Optical coherence tomography-guided monthly intravitreal ranibizumab injections delivered over the course of 1 year resulted in improved vision and reduced central retinal thickness.

AB - Purpose: To determine whether serial ranibizumab injections are effective in the treatment of cystoid macular edema in patients with chronic controlled noninfectious uveitis.Methods: Five eyes of 5 patients were included in a prospective noncomparative therapeutic trial. They received intravitreal injections of ranibizumab at Day 0 and were followed monthly for 1 year. Injections were repeated monthly if persistent or new cystic edema manifested on optical coherence tomography. The primary outcome measure was the mean change in best-corrected visual acuity from baseline at 12 months. Secondary outcome measures included mean percentage change in central subfield retinal thickness (CST) and incidence of adverse events through Month 24.Results: Thirty-two injections were performed over the study period. At 1 year, the mean increase in acuity was 12.2 Early Treatment for Diabetic Retinopathy Study letters (P = 0.015). There was a statistically significant increase in visual acuity over time (P = 0.002). The CST decreased by 31.4%, 46.0%, 37.6%, and 45.4% relative to baseline at 3, 6, 9, and 12 months, respectively (P = 0.003). One patient experienced recurrence of uveitis with subsequent cataract and glaucoma progression.Conclusion: Optical coherence tomography-guided monthly intravitreal ranibizumab injections delivered over the course of 1 year resulted in improved vision and reduced central retinal thickness.

KW - Anti-vascular endothelial growth factor

KW - Antiangiogenics

KW - Cystoid macular edema

KW - Ranibizumab

KW - Uveitic macular edema

KW - Uveitis

UR - http://www.scopus.com/inward/record.url?scp=84916641120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916641120&partnerID=8YFLogxK

M3 - Article

C2 - 25170857

AN - SCOPUS:84916641120

VL - 34

SP - 2431

EP - 2438

JO - Retina

JF - Retina

SN - 0275-004X

IS - 12

ER -